The Clinical Inadequacy of the Placebo Model and the Development of an Alternative Conceptual Framework

Psychotherapy and Psychosomatics

Volumn 86, Issue 6, 2017, Pages 332-340

  Fava, Giovanni A ^a,b   Guidi, Jenny ^a   Rafanelli, Chiara ^a   Rickels, Karl ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug treatment; Evidence based medicine; Illness behavior; Placebo; Psychotherapy; Self management; Tolerance; Treatment setting

Indexed keywords

CLOMIPRAMINE;

AGE; ARTICLE; CLINICAL PRACTICE; CONCEPTUAL FRAMEWORK; HEALTH STATUS; HEREDITY; HOUSING; HUMAN; ILLNESS BEHAVIOR; NUTRITION; OBSESSION; PATIENT SATISFACTION; PERSONALITY; PHYSICIAN ATTITUDE; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; SELF CARE; SEX; SOCIAL SUPPORT; STUDY DESIGN; TREATMENT OUTCOME; WELLBEING; WORK ENVIRONMENT; CLINICAL TRIAL (TOPIC); METHODOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; PLACEBO EFFECT; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85033382123     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000480038     Document Type: Article

References (73)

1. Schedlowski M, Enck P, Rief W, Bingel U: Neuro-bio-behavioral mechanisms of placebo and nocebo responses. Pharmacol Rev 2015; 67: 697-730.
2. Enck P, Bingel U, Schedlowski M, Rief W: The placebo response in medicine: minimize, maximize or personalize? Nature Rev 2013; 12: 191-204.
3. Kirsch I: Are drug and placebo effects in depression additive? Biol Psychiatry 2000; 4: 733-735.
4. Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders. Psychother Psychosom 2003; 72: 115-127.
5. Linden M: Placebo: unsolved problems for science, and simple conclusions for clinical practice. Am J Psychiatry 2017; 174: 91-92.
6. Miller FG, Kaptchuk TF: The power of context: reconceptualizing the placebo effect. J R Soc Med 2008; 101: 222-225.
7. Beecher HK: The powerful placebo. JAMA 1955; 159: 1602-1606.
8. Wolf S: The pharmacology of placebos. Pharmacol Rev 1959; 11: 689-704.
9. Rickels K (ed): Non-Specific Factors in Drug Therapy. Springfield, Thomas, 1968.
10. Price DD, Finniss DG, Benedetti F: A comprehensive review of the placebo effect. Annu Rev Psychol 2008; 59: 565-590.
11. Walach H: Placebo effects in complementary and alternative medicine: the self-healing response; in Colloca L, Flaten MA, Meissner K (eds): Placebo and Pain. From Bench to Bedside. Amsterdam, Academic Press, 2013, pp 189-202.
12. Roy R: Social Support, Health and Illness. Toronto, University of Toronto Press, 2011.
13. Shapiro AK, Morris LA: The placebo effect in medical and psychological therapies; in Garfield SL, Bergin AE (eds): Handbook of Psychotherapy and Behavior Change. New York, Wiley, 1978, pp 369-410.
14. Lasagna L, Mosteller F, von Felsinger J, Beecher HK: A study of the placebo response. Am J Med 1954; 16: 770-779.
15. Lasagna L, Laties VG, Dohan JL: Further study on the pharmacology of placebo administration. J Clin Invest 1958; 37: 533-537.
16. Rickels K: Psychopharmacologic agents. J Nerv Ment Dis 1963; 136: 540-549.
17. Hall KT, Kaptchuk TJ: Genetic biomarkers of placebo response: what could it mean for future trial design? Clin Investig 2013; 3: 311-314.
18. Bodenhemier T, Lorig K, Holman H, Grumback K: Patient self-management of chronic disease in primary care. JAMA 2002; 288: 2469-2475.
19. Marks IM, Lelliott P, Basoglu M, Noshirvani H, Monteiro W, Cohen D, Kasvikis Y: Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988; 152: 522-534.
20. Rickels K, Downing RZ, Howard K: Predictors of chlordiazepoxide response in anxiety. Clin Pharmacol Ther 1971; 12: 263-273.
21. Downing RW, Rickels K: Predictors of amitriptyline response in outpatient depressives. J Nerv Ment Dis 1972; 154: 248-263.
22. Levy SB: The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. New York, Plenum Press, 1992.
23. Moore TJ, Mattison DR: Adult utilization of psychiatric drugs and differences by sex, age and race. JAMA Intern Med 2017; 177: 274-275.
24. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Progr Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602.
25. Chouinard G, Chouinard V-A: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71.
26. Starcevic V, Brakoulias V, Viswasam K, Berle D: Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom 2015; 84: 379-380.
27. Chouinard G, Samaha AN, Chouinard V-A, Peretti C-S, Kanahara N, Takase M, Iyo M: Antipsychotic-induced dopamine supersensitivity psychosis. Psychother Psychosom 2017; 86: 189-219.
28. Fava GA, Tomba E, Bech P: Clinical pharmacopsychology: conceptual foundations and emerging tasks. Psychother Psychosom 2017; 86: 134-140.
29. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flyinn M, Harper L, Levy M, Rickels K, Pollack M: A double-blind placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadeqate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81: 87-97.
30. Tomba E: Nowhere patients. Psychother Psychosom 2012; 81: 69-72.
31. Fava GA, Tomba E, Tossani E: Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 306-311.
32. Downing RW, Rickels K: Nonspecific factors and their interaction with psychological treatment in pharmacotherapy; in Lipton MA, Di Mascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1419-1427.
33. Gliedman CH, Nash EH, Huber SD, Stone AR, Frank JD: Reduction of symptoms by pharmacologically inert substances and by short-term psychotherapy. AMA Arch Neurol Psychiatry 1958; 79: 345-351.
34. Park LC, Covi L: Non-blind placebo trial. Arch Gen Psychiatry 1965; 12: 336-345.
35. Schaefer M, Harke R, Denke C: Open-label placebos improve symptoms in allergic rhinitis. Psychother Psychosom 2016; 85: 373-374.
36. Uhlenhuth EH, Canter A, Neustadt JO, Payson HE: The symptomatic relief of anxiety with meprobamate, phenobarbital and placebo. Am J Psychiatry 1959; 115: 905-910.
37. Uhlenhuth EN, Rickels K, Fisher S, Park LC, Lipman RS, Mock J: Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy. Psychopharmacologia 1966; 9: 392-418.
38. Fava GA, Cosci F, Sonino N: Current psychosomatic practice. Psychother Psychosom 2017; 86: 13-30.
39. Lambert MJ: Maximizing psychotherapeutic outcome beyond evidence-based medicine. Psychother Psychosom 2017; 86: 80-89.
40. Zilcha-Mano S, Roose SP, Barber JP, Rutherford BR: Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels? Psychother Psychosom 2015; 84: 177-182.
41. Mechanic D: Sociological dimensions of illness behavior. Soc Sci Med 1995; 41: 1207-1216.
42. Sirri L, Fava GA, Sonino N: The unifying concept of illness behaviour. Psychother Psychosom 2013; 82: 74-81.
43. Magelli C, Fava GA, Grandi S, Semprini F, Bassein L, Capelletti D, Trombini G, Magnani B: Illness attitudes of patients suffering from mild heart failure during a pharmacological trial. Med Sci Res 1988; 16: 239-240.
44. Engel GL: The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129-136.
45. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J: Influence of context effects on health outcomes. Lancet 2001; 357: 757-762.
46. Fava GA, Rafanelli C, Guidi J, Sonino N: The clinical inadequacy of evidence-based medicine and the need of a conceptual framework based on clinical judgment. Psychother Psychosom 2015; 84: 1-3.
47. Fava GA: Evidence-based medicine was bound to fail: a report to Alvan Feinstein. J Clin Epidemiol 2017; 84: 3-7.
48. Downing RW, Rickels K: Self-report of hostility and the incidence of side reactions in neurotic outpatients treated with tranquillizing drugs and placebo. J Consult Psychol 1967; 31: 71-76.
49. Nelson JC, Jatlow PI, Quinlan DM: Subjective complaints during desipramine treatment. Arch Gen Psychiatry 1984; 41: 55-59.
50. Shapiro AK, Mike V, Barton H, Shapiro E: Study of the placebo effect with a self-administered test. Comp Psychiatry 1973; 14: 535-548.
51. Wolf S, Pinsky R: Effect of placebo administration and occurrence of toxic reactions. JAMA 1954; 155: 139-141.
52. Fisher S, Cole JO, Rickels K, Uhlenhuth EH: Drug-set interaction: the effects of expectations on drug response in outpatients; in Bradley PB, Flugel F, Hoch PH (eds): Neuropsychopharmacology. Amsterdam, Elsevier, 1964, vol 3, pp 149-156.
53. Horwitz RI, Singer BH, Makuch RW, Viscoli CM: Can treatment that is helpful on average be harmful to some patients? J Clin Epidemiol 1996; 49: 395-400.
54. Horwitz RI, Hayes-Conroy A, Singer BH: Biology, social environment, and personalized medicine. Psychother Psychosom 2017; 86: 5-10.
55. De las Cuevas C, de Leon J: Reviving research on medication attitudes for improving pharmacotherapy. Psychother Psychosom 2017; 86: 73-79.
56. Di Mascio A: Personality and variability of response to psychotropic drugs: relationship to "paradoxical" effects; in Rickels K (ed): Non-Specific Factors in Drug Therapy. Springfield, Thomas, 1968, pp 40-49.
57. Uhlenhuth EH, Lipman RS, Covi L: Combined pharmacotherapy and psychotherapy. J Nerv Ment Dis 1969; 148: 52-64.
58. Forand NR, de Rubeis RJ, Amsterdam JD: Combining medication and psychotherapy in the treatment of major mental disorders; in Lambert MJ (ed): Bergin and Garfield's Handbook of Psychotherapy and Behavior Change, ed 6. New York, Wiley & Sons, 2013, pp 735-774.
59. Robinson DS, Rickels K: Concerns about clinical drug trials. J Clin Psychopharmacol 2000; 20: 593-596.
60. Fava GA, Rafanelli C, Tomba E: The clinical process in psychiatry: a clinimetric approach. J Clin Psychiatry 2012; 73: 173-184.
61. Bech P: Clinimetric dilemmas in outcome scales for mental disorders. Psychother Psychosom 2016; 85: 323-326.
62. Guidi J, Tomba E, Cosci F, Park SK, Fava GA: The role of staging in planning psychotherapeutic interventions in depression. J Clin Psychiatry 2017; 78: 456-463.
63. Fava GA, Bech P: The concept of euthymia. Psychother Psychosom 2016; 85: 1-5.
64. Hasler G: Well-being. An important concept for psychotherapy and psychiatric neuroscience. Psychother Psychosom 2016; 85: 255-261.
65. Topp CW, Østergaard SD, Søndergaard S, Bech P: The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom 2015; 84: 167-176.
66. Blasco-Fontecilla H, Baca-Garcia E, Courtet P, Garcia Nieto R, de Leon J: Horror vacui emptiness might distinguish between major suicide repeaters and non-major suicide repeaters. Psychother Psychosom 2015; 84: 117-119.
67. De Leon J, Baca-Garcia E, Blasco-Fontecilla H: From the serotonin model of suicide to a mental pain model of suicide. Psychother Psychosom 2015; 84: 323-329.
68. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs. Psychother Psychosom 2016; 85: 270-288.
69. Mohr DC, Spring B, Freedland KE, Beckner V, Arean P, Hollon SD, Ockene J, Kaplan R: The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 2009; 78: 275-284.
70. Lipowski ZJ: Psychiatry: mindless or brainless, both or neither? Can J Psychiatry 1989; 35: 249-254.
71. Hoffmann TC, Del Mar C: Clinicians' expectations of the benefits and harms of treatments, screening and tests. JAMA Internal Med 2017; 177: 407-419.
72. Fava GA, Cosci F, Offidani E, Guidi J: Behavioral toxicity revisited: iatrogenic comorbidity in psychiatric evaluation and treatment. J Clin Psychopharmacol 2016; 36: 550-553.
73. Moncrieff J, Cohen D: Rethinking models of psychotropic drug action. Psychother Psychosom 2005; 74: 145-153.